Antiplatelets After Stenting

Antiplatelets After Stenting   Guest: Malcolm Bell, M.D. Host: Sharonne Hayes, M.D.   In this podcast, we discuss the rationale for shortening the duration of dual antiplatelet therapy after coronary stenting and continuing P2Y12 inhibitor in preference to continuing aspirin as monotherapy.  With this approach, the risk of significant bleeding is reduced significantly and with no corresponding increase in ischemic or thrombotic events.  This strategy is particularly attractive for patients who are considered to be at high-risk of bleeding or who suffer an actionable bleed. A P2Y12 inhibitor appears to more efficacious for long term secondary prevention than aspirin.   Topics Discussed: Changes in the use of dual antiplatelet therapy for patients undergoing coronary stenting.  Short DAPT and dropping the aspirin. Patient population ideal for monotherapy with a P2Y12 inhibitor. What do you do after 6 or 12 months of monotherapy – continue, or switch back to aspirin? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.